|1.||Falkenburg, J H Frederik: 11 articles (05/2015 - 07/2009)|
|2.||Dolstra, Harry: 9 articles (05/2015 - 03/2009)|
|3.||van der Voort, Robbert: 7 articles (05/2015 - 03/2009)|
|4.||Kester, Michel G D: 7 articles (05/2015 - 07/2009)|
|5.||Hobo, Willemijn: 6 articles (05/2015 - 11/2010)|
|6.||Schaap, Nicolaas: 5 articles (05/2015 - 11/2010)|
|7.||Fredrix, Hanny: 4 articles (05/2015 - 07/2009)|
|8.||Heemskerk, Mirjam H M: 4 articles (05/2015 - 01/2011)|
|9.||Maas, Frans: 4 articles (11/2014 - 11/2010)|
|10.||Korngold, Robert: 3 articles (06/2015 - 08/2006)|
12/14/2012 - "Another interesting application is the design of personalized miHA-based cancer therapies based on patient-donor pair-specific miHAs detected by this pipeline. "
08/24/2012 - "The compounds isolated were evaluated for their cytotoxic effects against 11 cancer cell lines and immortalized MIHA normal liver cells, and the test substances demonstrated selectivity toward the cancer cells. "
07/01/2012 - "Despite induction of robust MiHA-specific T cell responses and long-term persistence of alloreactive memory T cells specific for the tumor, often these T cells fail to respond efficiently to tumor relapse. "
11/25/2010 - "Dendritic cell (DC)-based vaccination boosting MiHA-specific T-cell immunity is an appealing strategy to prevent or counteract tumor recurrence, but improvement is necessary to increase the clinical benefit. "
07/01/2009 - "However, these MiHA-specific CD8+ T-cell responses do not result in complete eradication of tumor cells in all patients. "
11/15/2010 - "In this study, CD8+ T-cell clones were isolated from leukemia patients who entered complete remission after allo-SCT, and MiHA-specific T-cell clones were efficiently selected for analysis of recognition of a panel of EBV-transformed B cells positive for the HLA restriction elements of the selected T-cell clones. "
08/01/2011 - "Moreover, patients with relapsed leukemia after initial MiHA-specific T-cell responses displayed high PD-L1 expression on CD34(+) leukemia cells and increased PD-1 levels on MiHA-specific CD8(+) T cells. "
11/25/2010 - "Most importantly, PD-L knockdown DCs showed superior potential to expand MiHA-specific CD8(+) effector and memory T cells from leukemia patients early after donor lymphocyte infusion and later during relapse. "
06/01/2014 - "Additional studies revealed that UCC-DC and UCB-LC can efficiently expand minor histocompatibility antigen (MiHA) HA-1-specific cytotoxic T cells in the peripheral blood of leukemia patients and prime MiHA HA-1-specific and HA-2-specific cytotoxic T cells in vitro. "
11/24/2011 - "In the present study, we tested an alternative approach, adoptive immunotherapy with CD8+ T(M) from donors vaccinated against a single minor histocompatibility antigen (miHA) expressed by leukemia cells. "
|3.||Graft vs Host Disease (Graft-Versus-Host Disease)
06/01/2015 - "The full exploitation of allo-BMT, however, is greatly limited by the development of graft-versus-host disease (GVHD), which is mediated by the donor T cell response against the miHA expressed in the recipient's cells of the intestine, skin, and liver. "
06/01/1997 - "Immunodominance also plays a role in the development of lethal graft-vs.-host disease (GVHD) directed to miHA, by which B6 T cells were transplanted along with T-cell depleted bone marrow to irradiated (825 cGy) recipients of either the BALB.B or CXB RI strains. "
08/01/1996 - "T cell response to a single dominant MiHA causes graft-versus-host disease."
09/01/1985 - "We have been studying the mitogen hyporesponsiveness and immunosuppression induced in chronic murine graft-vs.-host disease (GVHD) induced across minor histocompatibility (MiHA) barriers. "
10/01/2009 - "The MHC-matched, minor histocompatibility Ag (miHA)-mismatched B10.BR-->CBA strain combination has been used to elucidate the immunobiology of graft-vs-host disease (GVHD) following allogeneic bone marrow transplantation. "
|4.||Hepatocellular Carcinoma (Hepatoma)
12/01/2004 - "Three hepatoma cell lines with different p53 statuses (HepG2, Huh-7 and Hep3B) and one non-tumorigenic immortalized liver cell line (MIHA) were used for an in vitro study. "
05/07/2012 - "The expression changes of Smad2, Smad3, Smad4, Smad7, TIEG1 and TIEG2 gene following treatment with TGF-β1 in a TGF-β-sensitive hepatocyte cell line (MIHA), a TGF-β-sensitive hepatoma cell line (Hep3B) and two TGF-β-insensitive hepatoma cell lines (HepG2 and Bel7404) were examined. "
09/01/2005 - "Compared with the MIHA cells, the hepatoma cell lines as well as HUVECs were found to be highly sensitive to the drugs in the aspect that FTY720 could induce G(1) arrest and apoptosis in the hepatoma cells. "
12/01/2004 - "FTY720 selectively induced cell apoptosis in hepatoma cell lines with overexpression of cleaved caspase-3 and caspase-9, but the same phenomena were not found in MIHA cells. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
01/01/1991 - "However, the possibility to recruit CTL populations targeting host MiHA expressed specifically on hematopoietic cells suggests a novel therapeutic strategy for the cure of hematopoietic malignancies. "
03/01/2011 - "TCRs directed against the minor histocompatibility antigen (MiHA) HA-1 are good candidates for TCR gene transfer to treat hematologic malignancies because of the hematopoiesis-restricted expression and favorable frequency of HA-1. "
07/01/2012 - "Allogeneic stem cell transplantation (allo-SCT) can cure hematological malignancies by inducing alloreactive T cell responses targeting minor histocompatibility antigens (MiHA) expressed on malignant cells. "
|1.||Minor Histocompatibility Antigens
|2.||Histocompatibility Antigens (Histocompatibility Antigen)
|4.||Protein Kinases (Protein Kinase)
|9.||Caspase 3 (Caspase-3)
|10.||Inhibitor of Apoptosis Proteins
|2.||Stem Cell Transplantation
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Heterologous Transplantation (Xenotransplantation)